Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02607618 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2
A Phase 3 study of Skin Structures and Soft Tissue Infections, sponsored by Motif Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 613
- Enrollment target
- 20
- Study locations
NCT02607618 is a Phase 3 study of Skin Structures and Soft Tissue Infections that has completed, run by Motif Bio. The registered enrollment target is 613 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT02607618, a Phase 3 study of Skin Structures and Soft Tissue Infections, has completed, sponsored by Motif Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 613 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG Iclaprim
Study Locations (20)
California
- California - Anaheim
- California - Buena Park
- California - Chula Vista
- California - La Palma
- California - Long Beach
- St. Mary Medical Center ER - Long Beach
Florida
- Florida - Hollywood
- Florida - Miami
- Florida - Miami
Other
- Argentina - Buenos Aires
- Argentina - Buenos Aires
- Belgium - Brussels
Washington
- Washington - Kennewick
- Washington - Richland
Georgia
- Georgia - Columbus
Montana
- Montana - Butte
Nevada
- Nevada - Las Vegas
New Jersey
- New Jersey - Somers Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-08-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02607618
The ClinicalTrials.gov registry entry for NCT02607618 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 613 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Motif Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Skin Structures and Soft Tissue Infections appearing as the primary indexed condition, and to 2 interventions - of which Vancomycin is the first listed.
NCT02607618 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Other.
Frequently Asked Questions
What is clinical trial NCT02607618 about?
NCT02607618 is a clinical study titled "Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2". This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.
What is the current status of trial NCT02607618?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 613 participants. The study started on 2015-11. Estimated completion is 2017-08-08.
What conditions does trial NCT02607618 study?
This clinical trial studies the following conditions: Skin Structures and Soft Tissue Infections.
What interventions are being tested in trial NCT02607618?
The interventions under investigation include: Vancomycin (DRUG), Iclaprim (DRUG).
Who is sponsoring clinical trial NCT02607618?
This trial is sponsored by Motif Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02607618 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Montana, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.